Sixteen previously treated patients received AZQ in a phase II study to test therapeutic efficacy in refractory small cell lung cancer. The dose and schedule of AZQ was 20 mg/m2 day 1 and 8, with treatments repeated every 28 days. No objective responses were noted among 16 evaluable patients. Myelosuppression was the major toxicity. AZQ does not appear to have antitumor activity in patients with previously treated small cell carcinoma.
a University Maryland Cancer Center (formerly BCRC), University of Maryland Hospital, 22 S. Greene Street, Baltimore, Maryland.
b Manitoba Cancer Research Foundation, Winnepeg Manitoba, Canada.
c NCI-Navy Oncology Branch, DCT, NCI Bethesda, Maryland.